Editor's note

This article was originally published on 24 April 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

Patent filings as R&D intelligence

Patent filing data represents one of the cleanest windows into industry R&D priorities, free from the selection bias inherent in press releases and conference presentations. VacZine Analytics' systematic analysis of vaccine-related patent filings through 2007 and into early 2008 revealed several trends that were not yet visible in clinical pipeline databases: a marked acceleration in adjuvant-related intellectual property, particularly around novel TLR agonists and emulsion-based adjuvant systems; a sustained focus on combination vaccine formulation technology; and early-stage patent activity in the RNA-based vaccine space that would not translate into visible clinical candidates for several more years.

Adjuvant IP: the quiet battle

GSK's AS-series adjuvant system - including AS01, AS02, AS03, and AS04 - had already generated substantial patent estates that would prove commercially critical. Competitive pressure from Novartis's MF59 adjuvant and Intercell's IC31 was driving a race to build adjuvant IP positions that would determine which companies could formulate the next generation of complex antigen+adjuvant vaccines. For companies without proprietary adjuvant technology, the options were limited to licensing, collaboration, or development of own-IP alternatives.

Adjuvant Patents Growth
+40%

Estimated increase in vaccine adjuvant-related patent filings between 2005 and 2007, driven by AS-series, TLR agonist, and novel emulsion technology programmes

"Adjuvant IP is the quiet battle of the vaccine industry - the companies that control the adjuvant platforms will have the formulation flexibility to dominate the next generation of complex vaccines."